Lakefront Biotherapeutics (GLPGF) Other Operating Expenses (2015 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Other Operating Expenses for 12 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Operating Expenses fell 81.24% year-over-year to $1.8 million in Q2 2026; TTM through Jun 2026 was $706.1 billion, a 681413.54% increase from a year earlier, with the FY2025 full-year figure at $60.4 billion, up 136851.6% from the prior year.
• Other Operating Expenses was $1.8 million for Q2 2026 at Lakefront Biotherapeutics, up from $1.3 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $705.6 billion in Q4 2025 and troughed at -$10.1 million in Q2 2024.
• A 5-year average of $39.2 billion and a median of $10.4 million in 2022 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses sank 168.69% in 2024 and surged 1174874.25% in 2025, its largest moves.
• Over 5 years, Other Operating Expenses stood at $6.8 million in 2022, then jumped by 106.07% to $14.0 million in 2023, then soared by 329.36% to $60.1 million in 2024, then surged by 1174874.25% to $705.6 billion in 2025, then tumbled by 100.0% to $1.8 million in 2026.
• The last three Other Operating Expenses figures came in at $1.8 million (Q2 2026), $1.3 million (Q1 2026), and $705.6 billion (Q4 2025), per Business Quant data.